Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease

Experimental Neurology

Volumn 234, Issue 2, 2012, Pages 417-427

  Sadan, O ^a   Shemesh, N ^b   Barzilay, R ^a   Dadon Nahum, M ^a   Blumenfeld Katzir, T ^b   Assaf, Y ^b   Yeshurun, M ^a   Djaldetti, R ^a   Cohen, Y ^b   Melamed, E ^a,b,c   Offen, D ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BrainStorm Cell Therapeutics Ltd   (Israel)

Author keywords

Huntington's disease; In vivo MRI; Mesenchymal stem cells; Neurotrophic factors; Quinilinic acid

Indexed keywords

APOMORPHINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; NEUROTROPHIC FACTOR; PLATELET DERIVED GROWTH FACTOR; QUINOLINIC ACID;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN MAPPING; BRAIN SIZE; CELL DIFFERENTIATION; CELL SECRETION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSION WEIGHTED IMAGING; EXCITOTOXICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; TASK PERFORMANCE;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NERVE GROWTH FACTORS; QUINOLINIC ACID; RATS;

EID: 84858150982     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.12.045     Document Type: Article

References (46)

1. Bachoud-Levi A.C., Gaura V., Brugieres P., et al. Effect of fetal neural transplants in patients with Huntington's disease 6years after surgery: a long-term follow-up study. Lancet Neurol. 2006, 5:303-309.
2. Basser P.J., Mattiello J., LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys. J. 1994, 66:259-267.
3. Behrstock S., Ebert A., Klein S., et al. Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant. 2008, 17:753-762.
4. Bradford J., Shin J.Y., Meredith R., et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. 2009, 106:22480-22485.
5. Cicchetti F., Saporta S., Hauser R.A., et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. 2009, 106:12483-12488.
6. Clarke D.J., Dunnett S.B., Isacson O., et al. Striatal grafts in rats with unilateral neostriatal lesions. Ultrastructural evidence of afferent synaptic inputs from the host nigrostriatal pathway. Neuroscience 1988, 24:791-801.
7. Dadon-Nachum M., Sadan O., Srugo I., et al. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Rev. Rep. 2011, 7(3):669-671.
8. Dey N.D., Bombard M.C., Roland B.P., et al. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav. Brain Res. 2010, 214:193-200.
9. Dunnett S.B., Carter R.J., Watts C., et al. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 1998, 154:31-40.
10. Faideau M., Kim J., Cormier K., et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum. Mol. Genet. 2010, 19:3053-3067.
11. Gharami K., Xie Y., An J.J., et al. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008, 105:369-379.
12. Giralt A., Friedman H.C., Caneda-Ferron B., et al. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther. 2010, 17:1294-1308.
13. Im W., Lee S.T., Park J.E., et al. Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice. PLoS Curr. HD 2010, 2.
14. Isacson O., Brundin P., Kelly P.A.T., et al. Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 1984, 311:458-460.
15. Jordi A., Pεrez-Navarro E., Canals J.M. Neurotrophic factors in Huntington's disease. Prog. Brain Res. 2004, 146:197-229.
16. Keene C.D., Sonnen J.N., Swanson P.D., et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007, 68:2093-2098.
17. Keene C., Chang R., Leverenz J., et al. A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 2009, 117:329-338.
18. Kells A.P., Fong D.M., Dragunow M., et al. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther. 2004, 9:682-688.
19. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
20. Lang A.E., Gill S., Patel N.K., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
21. Lee S.T., Chu K., Jung K.H., et al. Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann. Neurol. 2009, 66:671-681.
22. Levkovitch-Verbin H., Sadan O., Vender S., et al. Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest. Ophthalmol. Vis. Sci. 2010, 51:6394-6400.
23. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Bjorklund A., Widner H., Revesz T., Lindvall O., Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
24. McBride J.L., During M.J., Wuu J., et al. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 2003, 181:213-223.
25. Moseley M.E., Cohen Y., Mintorovitch J., et al. Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy. Magn. Reson. Med. 1990, 14:330-346.
26. Ogawa S., Lee T.M., Kay A.R., et al. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. 1990, 87:9868-9872.
27. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
28. Patel N.K., Bunnage M., Plaha P., et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005, 57:298-302.
29. Paxinos G., Watson C. The Rat Brain 1998, Academic Press. 4th ed.
30. Reuter I., Tali Y.F., Pavese N., et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2008, 79:948-951.
31. Rossignol J., Boyer C., Lévèque X., et al. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav. Brain Res. 2011, 217:369-378.
32. Sadan O., Shemesh N., Barzilay R., et al. Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells 2008, 26:2542-2551.
33. Sadan O., Bahat-Stroomza M., Barhum Y., et al. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev. 2009, 18:1179-1190.
34. Schmidt R.H., Bjorklund A., Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res. 1981, 218:347-356.
35. Shemesh N., Sadan O., Melamed E., et al. Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels. NMR Biomed. 2010, 23:196-206.
36. Snyder B.R., Chiu A.M., Prockop D.J., et al. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One 2010, 5:e9347.
37. Magnetic Resonance Imaging 1999, St. Louis, Misby. 3rd edition. D.D. Stark, W.G. Bradley (Eds.).
38. Tabrizi S.J., Cleeter M.W.J., Xuereb J., et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
39. Vazey E.M., Bronwen C. Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of Huntington disease. Stem Cell Res. Ther. 2010, 1:41.
40. Vazey E.M., Chen K., Hughes S.M., et al. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp. Neurol. 2006, 199:384-396.
41. Xie Y., Hayden M.R., Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 2010, 30:14708-14718.
42. Zeron M.M., Hansson O., Chen N., et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
43. Zuccato C., Ciammola A., Rigamonti D., et al. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
44. Zuccato C., Tartari M., Crotti A., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
45. Zuccato C., Liber D., Ramos C., et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2005, 52:133-139.
46. Zuccato C., Belyaev N., Conforti P., et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 2007, 27:6972-6983.